AAM
NTLA icon

Alphadyne Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Alphadyne Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,182
Closed -$131K – 1056
2026
Q1 		$131K Buy
+10,182
New +$130K ﹤0.01% 826

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Alphadyne Asset Management's NTLA Position: Q2 2026 in Review

Alphadyne Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 10,182 shares — an estimated $131K sold.

Alphadyne Asset Management first reported a position in NTLA in Q1 2026 and held it in 1 quarter. The position peaked at $131K in Q1 2026. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Alphadyne Asset Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Alphadyne Asset Management sold 10,182 Intellia Therapeutics shares in Q2 2026, an estimated $131K.
  • Alphadyne Asset Management first reported a position in Intellia Therapeutics in Q1 2026 and held it in 1 quarter.
  • Alphadyne Asset Management's Intellia Therapeutics position peaked at $131K in Q1 2026.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Alphadyne Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.